Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience

摘要: 522 Background: Cardiac toxicity associated with anthracylines and more recently herceptin used in adjuvant breast cancer treatment is well recognized. Little known about long term cardiac function as measured by left ventricular ejection fraction (LVEF) patients post therapy. We analyzed the database of a randomized Phase 3 NCIC CTG study to assess changes over time LVEF. Methods: Between 1989–1993, 710 pre/perimenopausal node positive were allocated receive CEF (cyclophosphamide (C) 75 mg/m2 po d 1–14, epirubicin (E) 60 IV fluorouracil (F) 500mg/m2 d1,d8) or CMF (C 100mg/m2 d1–14, methotrexate (M) 40mg/m2 F 600mg/m2 d1,8) given every 28 days for 6 cycles. The 10 year relapse-free survival was 52% (CEF) vs 45% (CMF), HR 1.31; stratified log rank, P=.007 (JCO, 2005,23;5166). LVEF on both arms at baseline, months 6, 12, 36, 60. Results: Compliance good measurements available 100% women 39% 40...